Avalo Therapeutics IncAVTX
Price$15.33

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $59K-86.6% YoYTTM through 30 Jun 2026
Net Income -$100.3MTTM through 30 Jun 2026
Free Cash Flow -$68.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-154,847.5%
Net Margin-170,055.9%

Returns

-28.7%ROE
-19.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.66x
Net Debt-$82Mnet cash position
Cash & Equivalents$85.4M

Quality Metrics

Altman Z-Score11.50
Piotroski F-Score3 / 9
FCF Margin-115,745.8%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $59K
Diluted EPS-$4.41TTM
'16'17'18'22'23'24'25
FY2025: $-5.84

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.